Haemonetics Corporation (HAE) - 10-K Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: April 2, 2005 (52 weeks)
Business Overview: Haemonetics is a market leader in automated blood processing systems, single-use disposables, and data management technology. The company operates as a single segment, divided into two product families: Donor Products (plasma, platelet, and red cell collection) and Patient Products (surgical blood salvage). Approximately 66% of revenues are generated outside the United States, with significant exposure to the Japanese Yen and Euro.
Key Financial Metrics (Fiscal Year 2005)
| Metric | 2005 | 2004 | Change |
|---|---|---|---|
| Net Revenues | $383.6 million | $364.2 million | +5.3% |
| Gross Profit | $197.9 million | $173.5 million | +14.0% |
| Gross Margin | 51.6% | 47.6% | +400 bps |
| Operating Income | $59.8 million | $47.3 million | +26.5% |
| Net Income | $39.6 million | $29.3 million | +35.2% |
| Diluted EPS | $1.52 | $1.19 | +27.7% |
| Cash & Equivalents | $185.8 million | $79.5 million | N/A |
| Total Debt | $45.8 million | $58.3 million | -21.3% |
| Working Capital | $255.7 million | $185.6 million | +37.8% |
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by favorable foreign exchange rates (contributing 5.0% of the increase). Organic growth was minimal (0.3%) due to a 15.0% decline in Plasma revenues offset by strong growth in Blood Bank (+16.2%), Red Cell (+28.5%), and Surgical (+12.7%) lines.
- Profitability: Operating income margin expanded to 15.6% from 13.0%. Gross margin improvement was driven by product mix shifts, reduced depreciation on customer-site equipment, and the absence of excess inventory provisions recorded in 2004.
- Legal Settlement: On May 20, 2005, an arbitration panel awarded the company $27.8 million in damages plus legal costs against Baxter International regarding supply contracts assumed from Alpha Therapeutic Corporation. This amount was not recorded in the 2005 financials as collection certainty was pending at the reporting date.
- Impairment Charge: A $1.7 million impairment charge was recognized in R&D expenses related to the write-down of an acquired intangible asset (other technology) due to a re-evaluation of deployment plans.
Guidance, Outlook, and Risks
- Market Trends: The commercial plasma market faces an oversupply of source plasma, leading to fewer collections. Conversely, the Red Cell market is growing due to shortages and the adoption of double red cell collection technology. The Surgical market is shifting toward orthopedic procedures (OrthoPAT) as open-heart surgeries decline.
- Product Pipeline: The company is focusing on five new products for introduction in fiscal 2006, including the cardioPAT surgical blood salvage system (limited release in April 2005) and the Cymbal automated red cell collector (CE marking expected in 2006).
- Accounting Changes: Adoption of SFAS No. 123R (Share-Based Payments) is required in fiscal 2007, which will significantly impact reported earnings by requiring fair value recognition of stock options.
- Risks: Significant exposure to foreign currency fluctuations (Yen and Euro); concentration of credit risk with the Japanese Red Cross Society (23.7% of 2005 revenues); and potential industry consolidation in the plasma sector.
Investor Verification Checklist
- Arbitration Recovery: Verify the timing and probability of collecting the $27.8 million arbitration award from Baxter International.
- Plasma Market Recovery: Monitor trends in the commercial plasma market to assess if the 15% revenue decline is a temporary oversupply issue or a structural shift.
- Foreign Exchange Sensitivity: Review the impact of the strengthening Yen and Euro on future margins, as 66% of revenue is international.
- Stock-Based Compensation: Assess the potential impact of SFAS 123R adoption in 2007 on future EPS, noting the pro-forma reduction in net income was approximately $5.3 million in 2005.
- Customer Concentration: Evaluate the risk associated with the Japanese Red Cross Society, which accounted for nearly 24% of total revenues.